LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

LLY

795.48

+0.43%↑

JNJ

152.14

-0.14%↓

ABBV

186.94

+0.72%↑

NVO

67.74

+0.61%↑

UNH

302.46

+0.12%↑

Search

Kymera Therapeutics Inc

Closed

SectorHealthcare

45.68 -1.55

Overview

Share price change

24h

Current

Min

43.75

Max

46.11

Key metrics

By Trading Economics

Income

5.2M

-66M

Sales

15M

22M

EPS

-0.82

Profit margin

-296.747

Employees

208

EBITDA

5.3M

-63M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+34% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

828M

3B

Previous open

47.23

Previous close

45.68

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Kymera Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Nov 2024, 03:00 UTC

Top News

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ

9 Jul 2024, 09:05 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

Peer Comparison

Price change

Kymera Therapeutics Inc Forecast

Price Target

By TipRanks

34% upside

12 Months Forecast

Average 62.27 USD  34%

High 79 USD

Low 51 USD

Based on 17 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

28.34 / 33.56Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.